DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Kinlytic (Urokinase) - Published Studies


Kinlytic Related Published Studies

Well-designed clinical trials related to Kinlytic (Urokinase)

Pharmacokinetics and safety of a new bioengineered thrombolytic agent, human tissue urokinase type plasminogen activator in Chinese healthy volunteers. [2011.01]

Efficacy and safety of 2-hour urokinase regime in acute pulmonary embolism: a randomized controlled trial. [2009.12.29]

[Thrombolysis of rabbit's pulmonary embolism with thrombus-targeted urokinase immune liposome] [2009.11]

Percutaneous treatment of intrabdominal abscess: urokinase versus saline serum in 100 cases using two surgical scoring systems in a randomized trial. [2009.07]

Use of urokinase in percutaneous drainage of large breast abscesses. [2009.04]

Intermittent intravenous urokinase for critical limb ischemia in diabetic foot ulceration. [2008.09]

Prevention of coagulase-negative staphylococcal central venous catheter-related infection using urokinase rinses: a randomized double-blind controlled trial in patients with hematologic malignancies. [2008.01.20]

Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: the middle cerebral artery embolism local fibrinolytic intervention trial (MELT) Japan. [2007.10]

Well-designed clinical trials possibly related to Kinlytic (Urokinase)

Ultrasound-accelerated thrombolysis for lower extremity ischemia: multicenter experience and literature review. [2011.08]

A high admission syndecan-1 level, a marker of endothelial glycocalyx degradation, is associated with inflammation, protein C depletion, fibrinolysis, and increased mortality in trauma patients. [2011.08]

Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6xFEC versus 3xFEC/3xDocetaxel. [2011.04.16]

Impact of uPA system gene polymorphisms on the susceptibility of environmental factors to carcinogenesis and the development of clinicopathology of oral cancer. [2011.03]

Effects of intra-articular administration of sodium hyaluronate on plasminogen activator system in temporomandibular joints with osteoarthritis. [2010.04]

[Multicentre clinical observation of anticoagulation and thrombolysis for the deep venous thrombosis] [2009.12.08]

Sodium citrate versus heparin catheter locks for cuffed central venous catheters: a single-center randomized controlled trial. [2009.06]

A multimodal concept in patients after severe aneurysmal subarachnoid hemorrhage: results of a controlled single centre prospective randomized multimodal phase I/II trial on cerebral vasospasm. [2009.05]

Frequency of sustained intracranial pressure elevation during treatment of severe intraventricular hemorrhage. [2009]

Value of transthoracic echocardiography in therapy regimens evaluation in pulmonary embolism. [2008.12]

[Treatment of great hematoma in brain hemorrhage with multi-point puncture and continuous irrigation-draining] [2008.10.28]

A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer. [2008.10]

Role of routine computed tomography in paediatric pleural empyema. [2008.10]

Heating of carbon dioxide during insufflation alters the peritoneal fibrinolytic response to laparoscopic surgery : A clinical trial. [2008.05]

Anti-angiogenic potential of CoenzymeQ10, riboflavin and niacin in breast cancer patients undergoing tamoxifen therapy. [2008.04]

Treatment of peritoneal dialysis-associated peritonitis: a systematic review of randomized controlled trials. [2007.12]

Comparison of alteplase and heparin in maintaining the patency of paediatric central venous haemodialysis lines: a randomised controlled trial. [2007.06]

Therapy for children with henoch-schonlein purpura nephritis: a systematic review. [2007.01.10]

Salmeterol enhances pulmonary fibrinolysis in healthy volunteers. [2007.01]

Other research related to Kinlytic (Urokinase)

The efficacy and safety of pharmacoinvasive therapy with prourokinase for acute ST-segment elevation myocardial infarction patients with expected long percutaneous coronary intervention-related delay. [2013]

Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmo Diet and Cancer Study. [2011.11.09]

Amiloride off-target effect inhibits podocyte urokinase receptor expression and reduces proteinuria. [2011.11.09]

Thrombosis of Tunneled-Cuffed Hemodialysis Catheters: Treatment With High-Dose Urokinase Lock Therapy. [2011.08.16]

Activation of the zymogen to urokinase-type plasminogen activator is associated with increased interdomain flexibility. [2011.08.12]

Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer. [2011.06.01]

Urokinase-type plasminogen activator contributes to heterogeneity of macrophages at the border of damaged site during liver repair in mice. [2011.05]

Urokinase receptor mediates mobilization, migration, and differentiation of mesenchymal stem cells. [2011.04.01]

Soluble urokinase plasminogen activator receptor during allogeneic stem cell transplantation. [2011.04]

Development of a kit to treat subarachnoid hemorrhage by intrathecal simple urokinase infusion (ITSUKI) therapy: preliminary results in patients with World Federation of Neurological Surgery (WFNS) grade V subarachnoid hemorrhage. [2011.03]

[Efficacy of regional administration of urokinase and argatroban via small saphenous vein catheter for treatment of acute deep venous thrombosis in the lower limb]. [2011.03]

Treatment of Budd-Chiari syndrome with urokinase following predilation in patients with old inferior vena cava thrombosis. [2011.02]

Catheter-directed thrombolysis with a continuous infusion of low-dose urokinase for non-acute deep venous thrombosis of the lower extremity. [2011.01]

Mutant prourokinase with adjunctive C1-inhibitor is an effective and safer alternative to tPA in rat stroke. [2011]

[Effects of acupoint-embedment of medicated-thread and acupoint-injection on expression of cortical urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in rats with cerebral ischemia-reperfusion injury]. [2010.12]

Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer. [2010.11.17]

[Effects of urokinase intervention on endotoxin-induced DIC in Wistar rat model]. [2010.11]

Local intra-arterial thrombolysis with urokinase for acute ischemic stroke before and after the approval of intravenous tissue plasminogen activator treatment in Taiwan. [2010.11]

Effect of recombinant single-chain urokinase-type plasminogen activator on experimental pulmonary embolism. [2010.10]

Evaluation of a pediatric protocol of intrapleural urokinase for pleural empyema: a prospective study. [2010.09]

Outcome in acute stroke with different intra-arterial infusion rate of urokinase on thrombolysis. [2010.09]

Once-daily intrapleural urokinase treatment of complicated parapneumonic effusion in pediatric patients. [2010.05]

An effective treatment for cerebral hemorrhage: minimally invasive craniopuncture combined with urokinase infusion therapy. [2010.05]

Modulators of the urokinase-type plasminogen activation system for cancer. [2010.05]

Use of intrathecal urokinase in repeated shunt and external ventricular drain blockage from high CSF protein due to an optic pathway glioma. [2010.05]

Inhibition of urokinase activity reduces primary tumor growth and metastasis formation in a murine lung carcinoma model. [2010.03.15]

[Urokinase in the management of occluded PICC lines] [2010.03]

Transradial approach for transcatheter selective superior mesenteric artery urokinase infusion therapy in patients with acute extensive portal and superior mesenteric vein thrombosis. [2010.02]

[Successful treatment of thoracic drainage using urokinase for empyema in an elderly man]. [2010]

An effective treatment for cerebral hemorrhage: minimally invasive craniopuncture combined with urokinase infusion therapy. [2010]

[The effect of urokinase on hepatic fibrogenesis in rats] [2009.12]

Rebleeding from a vertebral artery dissecting aneurysm after endovascular internal trapping: adverse effect of intrathecal urokinase injection or incomplete occlusion?-case report-. [2009.12]

[Effects of urokinase on renal interstitial fibrosis and transforming growth factor-beta1 in the kidney of rats with chronic cyclosporine A nephropathy] [2009.12]

Triclosan inhibits tumor necrosis factor-alpha-stimulated urokinase production in human gingival fibroblasts. [2009.12]

Radial arterial approach with adjunctive urokinase for treating occluded autogenous radial-cephalic fistulas. [2009.11]

Urokinase plasminogen activator system as a potential target for cancer therapy. [2009.11]

Chemical conjugation of urokinase to magnetic nanoparticles for targeted thrombolysis. [2009.10]

Downregulation of matrix metalloprotease-9 and urokinase plasminogen activator by TX-1877 results in decreased tumor growth and metastasis on xenograft model of rectal cancer. [2009.10]

Single-chain urokinase in empyema induced by Pasturella multocida. [2009.10]

Low-dose urokinase in massive pulmonary embolism when standard thrombolysis is contraindicated. [2009.10]

Intraperitoneal urokinase and oral rifampicin for persisting asymptomatic dialysate infection following acute coagulase-negative staphylococcus peritonitis. [2009.09]

Keeping CSF valve function with urokinase in children with intra-ventricular haemorrhage and CSF shunts. [2009.08]

Urokinase perfusion prevents intrahepatic ischemic-type biliary lesion in donor livers. [2009.07.28]

Targeting the urokinase plasminogen activator receptor with a monoclonal antibody impairs the growth of human colorectal cancer in the liver. [2009.07.15]

Cigarette smoke condensate stimulates urokinase production through the generation of reactive oxygen species and activation of the mitogen activated protein kinase pathways in human gingival fibroblasts. [2009.06]

Dynamical levels of plasma F(1+2) and D-dimer in patients with acute cerebral infarction during intravenous urokinase thrombolysis. [2009.05]

The effects of blood pressure and urokinase on brain injuries after experimental cerebral infarction in rats. [2009.03]

Inhibition of integrin alphavbeta3 prevents urokinase plasminogen activator-mediated impairment of cerebrovasodilation after cerebral hypoxia/ischemia. [2009.03]

Inhalation of urokinase-type plasminogen activator reduces airway remodeling in a murine asthma model. [2009.03]

The urokinase plasminogen activator system: a target for anti-cancer therapy. [2009.02]

Targeting the urokinase plasminogen activator receptor with synthetic self-assembly nanoparticles. [2009.01]

Therapeutic potential of siRNA-mediated targeting of urokinase plasminogen activator, its receptor, and matrix metalloproteinases. [2009]

Effectiveness of combining continuous cerebrospinal drainage and intermittent intrathecal urokinase injection therapy in preventing symptomatic vasospasm following aneurysmal subarachnoid haemorrhage. [2008.10]

Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy. [2008.09.15]

[Correlation of the content and expression of urokinase plasminogen activator with asthenospermia in rat models] [2008.09]

Cost-effectiveness of urokinase and alteplase for treatment of acute peripheral artery disease: comparison in a decision analysis model. [2008.08.01]

Both tissue-type plasminogen activator and urokinase prevent intraabdominal abscess formation after surgical treatment of peritonitis in the rat. [2008.07]

[Effect of urokinase on renal interstitial inflammation in rats with chronic cyclosporine A nephropathy and its possible mechanism.] [2008.05]

Plasminogen activator inhibitor type 1 is the most significant of the usual tissue prognostic factors in node-negative breast ductal adenocarcinoma independent of urokinase-type plasminogen activator. [2008.04]

Other possibly related research studies

Thrombolysis for acute ischaemic stroke. [2009.10.07]

[Right-sided prosthetic cardiac valve thrombosis: value of cinefluoroscopy in the diagnosis and follow-up of thrombolytic treatment] [2009.10]

Treatment of acute limb ischemia with focus on endovascular techniques. [2009.05]

Therapeutic administration of plasminogen activator inhibitor-1 prevents hypoxic-ischemic brain injury in newborns. [2009.07.08]

Receptor-targeted nanoparticles for in vivo imaging of breast cancer. [2009.07.15]

Combined histomorphologic and immunohistochemical phenotype to predict the presence of vascular invasion in colon cancer. [2009.06]

Predictors of the outcome of thrombolytic therapy in prosthetic mitral valve thrombosis: a study of 62 events. [2009.05]

Acute extensive portal and mesenteric venous thrombosis after splenectomy: treated by interventional thrombolysis with transjugular approach. [2009.06.28]

Does the concomitant intra-arterial injection of asialoerythropoietin and edaravone mitigate ischaemic mucosal damage after acute superior mesenteric artery thromboembolism in a rabbit autologous fibrin clot model? [2009.06.22]

Acute embolic occlusion of the left common iliac artery treated with intra-arterial thrombolysis and percutaneous thrombectomy. [2009.06]

[Individualized endovascular treatment of cerebral venous thrombosis: analysis of 168 patients] [2009.01.20]

[Unilateral Raynaud's phenomenon with intensification when the arms are elevated] [2009]

Intra-arterial thrombolysis for acute central retinal artery occlusion. [2009.05]

Antineoplastic effect of iodine in mammary cancer: participation of 6-iodolactone (6-IL) and peroxisome proliferator-activated receptors (PPAR). [2009.06.06]

Thrombolytic therapy for femoral artery thrombosis after left cardiac catheterization in children. [2009.04.20]

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017